Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer? - Takeaway - MDSpire
Clinical Guidelines

Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer?

Circulating tumor DNA (ctDNA) may be used to predict metastatic risk and identify which patients with muscle-invasive bladder cancer are more likely to benefit from a bladder-sparing treatment approac...

Share

  • 1

    ctDNA offers insights into metastatic risk in muscle-invasive bladder cancer.

  • 2

    RETAIN trials assess bladder-sparing treatment strategies.

  • 3

    Post-treatment ctDNA negativity predicts metastasis-free outcomes.

  • 4

    RETAIN-2 trials had 80.3% of participants metastasis-free at 29.2 months.

  • 5

    Limitations include challenges in detecting local recurrences.

  • 6

    Future trials aim to refine predictive biomarkers for treatment decision-making.

  • 7

    Importance of active surveillance in managing bladder cancer patients.

  • 8

    ctDNA testing shows promise in personalizing patient care.

Original Source(s)

Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer?

  • by The ASCO Post Staff

  • April 7, 2026

Related Content

Analysis Shows Nearly 7% of Global Clinical Trials Are Impacted by Middle East Disruption

Oncology trials account for a substantial proportion of impacted activity, with non–small cell lung cancer representing the most affected indication, followed by breast cancer.

Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer

As reported in The New England Journal of Medicine by Vulsteke et al, the phase III KEYNOTE-905/EV-303 trial has shown improved event-free and overall survival with the addition of perioperative enfor...

Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer

The combination of the NECTIN4-directed antibody drug conjugate enfortumab vedotin-ejfv and the immunotherapy drug pembrolizumab is the established first-line standard-of-care treatment for patients w...